Study supports palonosetron's delayed phase CINV action
New data presented at the 33rd European Society of Medical Oncology Congress in Stockholm, Sweden, may contribute to explaining why palonosetron, Helsinn's second generation 5-HT3 receptor antagonist, demonstrates in clinical trials and practice a unique long-lasting action in the prevention of chemotherapy-induced nausea and vomiting.
A single intravenous dose of palonosetron (0.25mg) provides better protection from CINV than first-generation 5-HT3 receptor antagonists, such as ondansetron and granisetron, throughout a five-day post-chemotherapy period, according to the Swiss drugmaker, noting that this means that a single dose of palonosetron also grants protection during the delayed phase of CINV.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze